Provided by Tiger Trade Technology Pte. Ltd.

Ionis Pharmaceuticals

83.10
-1.1927-1.41%
Volume:321.50K
Turnover:26.60M
Market Cap:13.46B
PE:-51.51
High:84.96
Open:84.21
Low:82.00
Close:84.29
52wk High:86.74
52wk Low:23.95
Shares:161.97M
Float Shares:161.00M
Volume Ratio:0.30
T/O Rate:0.20%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6132
EPS(LYR):-3.0358
ROE:-40.04%
ROA:-5.68%
PB:21.78
PE(LYR):-27.37

Loading ...

Press Release: Ionis to hold fourth quarter and full year 2025 financial results webcast

Dow Jones
·
Yesterday

Ionis Pharmaceuticals CEO Brett P. Monia Reports Sale of Common Shares

Reuters
·
Yesterday

Ionis Pharmaceuticals (IONS) Valuation Check As Dawnzera Approval And Other Milestones Support Growth Prospects

Simply Wall St.
·
Feb 08

Ionis Pharmaceuticals Is Maintained at Overweight by Piper Sandler

Dow Jones
·
Feb 07

Ionis Pharmaceuticals price target raised to $87 from $77 at Piper Sandler

TIPRANKS
·
Feb 06

Ionis Pharmaceuticals EVP and Chief Scientific Officer Frank Bennett Reports Disposal of Common Shares

Reuters
·
Feb 03

Ionis Pharmaceuticals EVP Chief Business Officer Joseph Baroldi Reports Sale of Common Shares

Reuters
·
Feb 03

Has Ionis Pharmaceuticals (IONS) Run Too Far After Its 152% One Year Surge?

Simply Wall St.
·
Jan 30

Ionis Pharmaceuticals assumed with an Overweight at Barclays

TIPRANKS
·
Jan 28

Why Ionis Pharmaceuticals (IONS) Is Up 5.2% After EU Approval of DAWNZERA for HAE Prevention

Simply Wall St.
·
Jan 24

Ionis Pharmaceuticals EVP Shannon L. Devers Reports Sale of Common Shares

Reuters
·
Jan 24

Ionis Pharmaceuticals announces European Commission approval for Dawnzera

TIPRANKS
·
Jan 21

BRIEF-Dawnzera™ (Donidalorsen) Approved In The European Union For Hereditary Angioedema (Hae)

Reuters
·
Jan 21

EU Approves Ionis Pharmaceuticals' DAWNZERA for Hereditary Angioedema Prevention

Reuters
·
Jan 21

Dawnzera™ (Donidalorsen) Approved in the European Union for Hereditary Angioedema (Hae)

THOMSON REUTERS
·
Jan 21

Ionis Pharmaceuticals Inc - Eligible for Milestone Payment of $15 Mln and Tiered Royalties of up to 30% on Net Product Sales

THOMSON REUTERS
·
Jan 21

Ionis Pharmaceuticals EVP and Chief Scientific Officer Frank Bennett Reports Sale of Common Shares

Reuters
·
Jan 21

Analysts Have Conflicting Sentiments on These Healthcare Companies: Hims & Hers Health (HIMS) and Ionis Pharmaceuticals (IONS)

TIPRANKS
·
Jan 19

Analysts Are Bullish on Top Healthcare Stocks: Healthequity (HQY), Ionis Pharmaceuticals (IONS)

TIPRANKS
·
Jan 19

Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD), Ionis Pharmaceuticals (IONS) and DENTSPLY SIRONA (XRAY)

TIPRANKS
·
Jan 16